From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

被引:11
作者
Chen, Qichen [1 ]
Mao, Rui [1 ]
Zhao, Jianjun [1 ]
Bi, Xinyu [1 ]
Li, Zhiyu [1 ]
Huang, Zhen [1 ]
Zhang, Yefan [1 ]
Zhou, Jianguo [1 ]
Zhao, Hong [1 ]
Cai, Jianqiang [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hepatobiliary Surg, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr, Beijing, Peoples R China
来源
CANCER MEDICINE | 2020年 / 9卷 / 21期
基金
中国国家自然科学基金;
关键词
colorectal cancer liver metastasis; neoadjuvant chemotherapy; outcomes; time to surgery; PATHOLOGICAL COMPLETE RESPONSE; HEPATIC RESECTION; TUMOR-RESPONSE; RECTAL-CANCER; IMPACT; TIME; CHEMORADIOTHERAPY; INTERVAL; SCORE; CHEMORADIATION;
D O I
10.1002/cam4.3283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Neoadjuvant chemotherapy (NAC) has been widely performed in the treatment of colorectal cancer liver metastasis (CRLM) patients, but the optimal timing of surgery after NAC is unclear. The aim of this study was to investigate the optimal timing of surgery. Methods From December 2010 to May 2018, 101 consecutive patients who received NAC followed by liver resection for CRLM were included in this study. The main outcome parameters were pathological response, progression-free survival (PFS), and overall survival (OS). The effect of time to surgery (TTS) on patient outcomes, defined as a high TTS and a low TTS according to an X-tile analysis, was investigated. To adjust for potential selection bias, propensity score matching at 1:2 was performed with two high TTS patients matched to one low TTS patient. Kaplan-Meier curves, logistic regression analyses, and Cox regression models were used for the data analysis. Results The optimal cut-off value for the TTS was 5 weeks by X-tile analysis. The patients in this study were divided into low (<= 5 weeks, n = 27) and high (>5 weeks, n = 74) TTS groups. Patients with a high TTS were more likely to have an unfavorable pathological response (75.7% vs 48.1%,P = .008). In multivariate analysis, a low TTS significantly predicted a better pathological response (OR = 3.397, 95% CI: 1.116-10.344,P = .031). Compared to patients with a high TTS, patients with a low TTS had significantly better PFS (P < .001, mPFS: 16 months vs 7 months) and better OS (P = .037, mOS: not reached vs 36 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 2.041, 95% CI: 1.152-3.616,P = .014) but not OS. After propensity matching, the patients with a low TTS had significantly better PFS (P < .001, mPFS: 18.2 months vs 10 months) and an equivalent OS (P = .115, mOS: not reached vs 41 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 3.031, 95% CI: 1.494-6.149,P = .002) but not OS. Conclusion The longer TTS after the completion of NAC may be disadvantageous for a favorable pathological response and long-term PFS. These results should be validated prospectively in a randomized trial.
引用
收藏
页码:7849 / 7862
页数:14
相关论文
共 37 条
  • [1] [Anonymous], 2010, COMMON TERMINOLOGY C
  • [2] Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas A Summary of 480 Cases
    Becker, Karen
    Langer, Rupert
    Reim, Daniel
    Novotny, Alexander
    zum Buschenfelde, Christian Meyer
    Engel, Jutta
    Friess, Helmut
    Hofler, Heinz
    [J]. ANNALS OF SURGERY, 2011, 253 (05) : 934 - 939
  • [3] BELL RS, 1988, CANCER RES, V48, P5533
  • [4] Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology
    Benson, Al B., III
    Venook, Alan P.
    Cederquist, Lynette
    Chan, Emily
    Chen, Yi-Jen
    Cooper, Harry S.
    Deming, Dustin
    Engstrom, Paul F.
    Enzinger, Peter C.
    Fichera, Alessandro
    Grem, Jean L.
    Grothey, Axel
    Hochster, Howard S.
    Hoffe, Sarah
    Hunt, Steven
    Kamel, Ahmed
    Kirilcuk, Natalie
    Krishnamurthi, Smitha
    Messersmith, Wells A.
    Mulcahy, Mary F.
    Murphy, James D.
    Nurkin, Steven
    Saltz, Leonard
    Sharma, Sunil
    Shibata, David
    Skibber, John M.
    Sofocleous, Constantinos T.
    Stoffel, Elena M.
    Stotsky-Himelfarb, Eden
    Willett, Christopher G.
    Wu, Christina S.
    Gregory, Kristina M.
    Freedman-Cass, Deborah
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (03): : 370 - 398
  • [5] Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI [10.1158/1078-0432.CCR-04-0713, DOI 10.1158/1078-0432.CCR-04-0713]
  • [6] Impact of the Time Interval from Neoadjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and Peritoneal Cancer Patients
    Chen, Ming
    Chen, Zhanpeng
    Xu, Manman
    Liu, Duo
    Liu, Tianyu
    He, Mian
    Yao, Shuzhong
    [J]. JOURNAL OF CANCER, 2018, 9 (21): : 4087 - 4091
  • [7] Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases
    Chen, Qichen
    Wu, Chaorui
    Zhao, Hong
    Wu, Jianxiong
    Zhao, Jianjun
    Bi, Xinyu
    Li, Zhiyu
    Huang, Zhen
    Zhang, Yefan
    Zhou, Jianguo
    Cai, Jianqiang
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2020, 24 (03) : 659 - 670
  • [8] Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018
    Zhang, Suzhan
    Li, Jin
    Cai, Sanjun
    Chen, Gong
    Cai, Muyan
    Chen, Gong
    Gao, Yuanhong
    Lai, Maode
    Li, Guichao
    Li, Xinxiang
    Liang, Houjie
    Nan, Kejun
    Ren, Li
    Sheng, Weiqi
    Wang, Yi
    Wang, Xicheng
    Xu, Jianmin
    Xu, Ruihua
    Yuan, Ying
    Zhang, Zhen
    Zhou, Aiping
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2019, 31 (01) : 117 - 134
  • [9] Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
    Dindo, D
    Demartines, N
    Clavien, PA
    [J]. ANNALS OF SURGERY, 2004, 240 (02) : 205 - 213
  • [10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247